Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Schistosoma japonica and tetanus bivalent oral or nose-dripping vaccine

A technology of host bacteria and expression vectors, applied in the field of vaccines, can solve problems such as inability to meet the needs of vaccines, and achieve the effect of improving immune protection and promoting enhancement

Inactive Publication Date: 2017-09-19
SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Traditional vaccine development technology can no longer meet the needs of today's vaccines. It is necessary to combine a variety of new concepts, new technologies, and high-efficiency vaccine platforms to achieve the goal together.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Schistosoma japonica and tetanus bivalent oral or nose-dripping vaccine
  • Schistosoma japonica and tetanus bivalent oral or nose-dripping vaccine
  • Schistosoma japonica and tetanus bivalent oral or nose-dripping vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] The inventors of the present application used the Schistosoma japonicum 26kDa GST (Sj26GST) protein as a model antigen in the previous research, and used the Bacillus subtilis expression plasmid pUS186 to construct the Sj26GST gene in the downstream of the Bacillus subtilis capsid gene CotC promoter and its coding sequence, at WB600 The exogenous protein Sj26GST was highly expressed on the surface of spore capsid in the extracellular enzyme-deficient strain.

[0059] Using the Bacillus subtilis shuttle integration plasmid pDG1664, CotC-Sj26GST-TTFC was integrated into the chromosome of Bacillus subtilis through double crossover replacement, and fused with CotC to express on the outer surface of the spore capsid; at the same time, the CotB-peptide linker was integrated using the Bacillus subtilis shuttle integration plasmid pDG364 - IL-2 is integrated into the chromosome of Bacillus subtilis through double crossover replacement, and is fused with CotB to express on the ou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a construction method and an immunity evaluation system of a spore probiotic mucosa vaccine, and provides a dual-transposition expression vector and a host cell capable of expressing a causal organism exogenous antigen. The invention also provides a probiotic vaccine vector for fusion expressing a cell factor IL-2. The invention also provides a schistosoma japonica and tetanus bacillus bivalent vaccine, and a schistosoma japonica univalent vaccine. A probiotic vaccine is a mucosa delivery vector adopting spore bacillus subtilis as an oral or nose-dripping way. According to the schistosoma japonica and tetanus bacillus bivalent vaccine provided by the invention, schistosoma japonica Sj26GST, tetanus TTFC and other exogenous genes, the cell factor IL-2 and a brevibacterium mucosal immunity vaccine vector are organically combined for the first time and have complementary advantages. The Sj26GST and the TTFC are selected as model antigens, a spore vector delivery model antigen is utilized, and a spore and the recombinant IL-2 expressed by the spore are used as adjuvants, so that an immune type is adjusted, and an immune reaction level is improved.

Description

technical field [0001] The invention relates to a vaccine, in particular to a bivalent vaccine with IL-2 as an adjuvant and spore-type probiotics as a mucosal delivery carrier. Background technique [0002] Using a new generation of nano-scale biological carrier, that is, nano-scale spores of Bacillus subtilis as a mucosal delivery vehicle to develop oral or nasal vaccines, it is estimated that industrial production within one month can meet the needs of high-risk populations for immunity. The spore vaccine produced by fermentation technology has greatly shortened the culture time compared with traditional chicken embryo vaccine, and the estimated unit cost per dose is only 1 / 10 of the production cost of traditional methods. Therefore, new vaccines with short research and development cycle, fast production, low cost, strong anti-interference ability to the external environment, easy storage and transportation, long-lasting cross-protection effect, and adjuvant effect have be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/21A61K39/00A61K39/08A61K39/39A61P33/12A61P31/04C12R1/125
CPCA61K38/2013A61K39/0003A61K39/08A61K39/12A61K39/39A61K48/005C12N1/20C12N15/75C07K14/005C07K14/32C07K14/33C07K14/43559C07K14/55A61K2039/523A61K2039/541A61K2039/53A61K2039/543A61K2039/542A61K2039/552A61K2039/55533A61K2039/57A61K2039/70C12N2760/16134Y02A50/30
Inventor 李丽陆家海
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com